Source: European Parliament
In August 2020, the Commission, acting on behalf of participating Member States and the company AstraZeneca, entered into an Advance Purchase Agreement (‘EU APA’) for the supply of 300 million doses of the COVID-19 vaccine under development by AstraZeneca.
The APA remained in force until March 2022, when the final doses purchased under the APA were delivered to the Participating Member States. The withdrawal of the marketing authorisation for Vaxzevria in March 2024 did not affect the implementation of the APA.
The date of the marketing authorisation withdrawal does also not impact the company’s liability or obligation to provide compensation for side effects from vaccines administered prior to the withdrawal, in line with the terms of the APA.